Russian Heart Failure Journal 2010year Prognostic impact of tissue inhibitor of matrix metalloproteinase-I (TIMP-I) in patients with CHF

To access this material please log in or register

Register Authorize

Prognostic impact of tissue inhibitor of matrix metalloproteinase-I (TIMP-I) in patients with CHF

Solomakhina N. I., Belenkov Y. N.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: metalloproteinase, prognosis, CHF

DOI: 10.18087/rhfj.2010.5.1405

Background. Increased activity of matrix metalloproteinases is associated with increased risk of cardiovascular events. Objective. To study prognostic role of matrix metalloproteinases I tissue inhibitor (TIMP-I) in patients with CHF. Materials and methods. 47 elderly patients with mostly III and IV CHF FC (NYHA) (mean age 80.0±1.2 years) were followed-up during 3 months. Sex- and age-matched control group included 14 patients without manifestation of CHF. Serum TIMP-I was measured with solid-phase ELISA. Results. During follow-up 16 patients of main- and 3 of control group died. Significant difference in TIMP-I levels between died patients and survivors in study group was observed (876.4±74.6 and 596.7±31.3 ng / ml, p<0.001) as well as in control group (1020.0±144.8 и 614.5±45.9 ng / ml, p<0.001). Thus, since there is low correlation between symptoms and severity of cardiac dysfunction in CHF, measurement of blood biomarkers level can be useful for disease prognosis evaluation.
  1. Denhardt DT, Feng B, Edwards DR et al. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther. 1993;59 (3):329–341.
  2. Nagase H, Suzuki K, Itoh Y et al. Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation. Adv Exp Med Biol. 1996;389:23–31.
  3. Liu J, Xiong W, Baca-Regen L et al. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg. 2003;38 (6):1376–1383.
  4. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74 (2):111–122.
  5. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21 (14):2245–2252.
  6. Sundstrom J, Evans JC, Benjamin EJ et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J. 2004;25 (17):1509–1516.
  7. Lubos E, Schnabel R, Rupprecht HJ et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J. 2006;27 (2):150–156.
  8. Blankenberg S, Rupprecht HJ, Poirier O et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107 (12):1579–1585.
  9. Cavusoglu E, Ruwende C, Chopra V et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J. 2006;151 (5):1101.e1–8.
  10. Jordán A, Roldán V, García M et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med. 2007;262 (3):385–392.
  11. Wilson EM, Gunasinghe HR, Coker ML et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002;8 (6):390–398.
  12. West MJ, Nestel PJ, Kirby AC et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J. 2008;29 (7):923–931.
  13. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: Framingham study. J Am Coll Cardiol. 1993;22 (4 suppl A):6A-13A.
  14. Sahn DJ, DeMaria A, Kisslo J, Weyman J. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58 (6):1072–1083.
  15. Tziakas DN, Chalikias GK, Parissis JT et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol. 2004;94 (2-3):269–277.
  16. Костюкевич О. И., Хадышьян Г. Г. Коррекция системного воспаления методом нутритивной поддержки у пациентов с ХСН III–IV ФК. Журнал Сердечная недостаточность, 2005;6 (5);186–190.
  17. Беленков Ю. В., Агеев Ф. Т., Мареев В. Ю. Нейрогормоны и цитокины при сердечной недостаточности: новая теория старого заболевания? Сердечная Недостаточность. 2000;1 (4):135–138.
  18. Арутюнов Г. П.,Кафарская Л. И., Власенко В. К. и др. Биоценоз кишечника и сердечно-сосудистый континиум. Сердечная недостаточность. 2004;5 (5):224–229.
  19. Ситникова М. Ю., Максимова Т. А., Вахрамеева Н. В. и др. Состояние эндотелия и маркеры хронического воспаления у больных ИБС, осложненной сердечной недостаточностью. Сердечная недостаточность. 2002;2 (2):89–92.
  20. Арутюнов Г. П., Кафарская Л. И., Былова Н. А. и др. Качественные и количественные показатели микрофлоры толстого кишечника при различных функциональных классах хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2005;6 (5):176–180.
  21. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103 (13):1813–1818.
  22. Ridker PM, Rifai N, Stampler MJ et. al. Plasma concentration of interleukin-6 and the risk of future myocardial among apparently healthy men. Circulation. 2000;101 (15):1767–1772.
  23. Harris TB, Ferrucci L, Tracy RP et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106 (5):506–512.
  24. Strandberg TE, Tivis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler. Thromb Vasc biol. 2000;20 (4):1057–1060.
  25. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 1991;12 (3):315–321.
  26. Marantz PR, Tobin JN, Wassertheil-Smoller S et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 1988;77 (3):607–612.
Solomakhina N. I., Belenkov Y. N. Prognostic impact of tissue inhibitor of matrix metalloproteinase-I (TIMP-I) in patients with CHF. Russian Heart Failure Journal. 2010;11(5):281-284.

To access this material please log in or register

Register Authorize
Ru En